| |
|
|
|
Xtalks, online
2023 -10-03
Advances in biomarker testing are revolutionizing strategies for diagnosing and managing neurological disorders and shifting the current treatment paradigm to a more personalized approach. Testing has always played a role in the management of mild cognitive impairment or early-stage Alzheimer’s disease (AD) patients. With the availability of disease-modifying therapies (DMTs), removing barriers to testing now has become an even more critical need to ensure that all eligible patients are tested to identify those that could benefit from therapy. However, the testing paradigm in AD is a complex one – multiple biomarkers and several different modalities including imaging and clinical lab testing exist.
This expert panel will discuss the current AD biomarker testing landscape including opportunities and some key barriers such as test awareness, availability, and reimbursement. The discussion will also highlight ways to address some of these challenges, including building evidence to demonstrate and communicate the value of testing in the management of AD.
Register here for this webinar to learn how to identify and overcome challenges in Alzheimer’s disease biomarker testing.
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Pete Riccelli, PhD, Senior Director, Precision Medicine, Commercial Strategy and Market Access, Veranex Catheline Plaideau, PhD, Sr. Manager, Precision Medicine, Commercial Strategy and Market Access, Veranex External Speakers
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2023 -10-03
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|